Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Inclusion Criteria: Subjects must meet one of the following criteria: * Subjects suspected of or diagnosed with the following Stage IV/metastatic or recurrent malignancies: * Lung: Non-small Cell Lung Cancer (NSCLC) * Skin: Cutaneous Malignancy, excluding Uveal Melanoma * Esophageal Cancer * Cervical Cancer * Endometrial Cancer * Colon Cancer: Mismatch repair deficient (dMMR) CRC only * All solid tumors with high tumor mutation burden (TMB) * All solid tumors that are microsatellite instability high (MSI-H) * All mismatch repair deficient (dMMR) solid tumors * Liver Cancer * Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with immune checkpoint inhibitor (ICI) therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate laboratory developed tests (LDTs) that, per clinician, render the patient eligible for ICI therapy, either frontline or a later line. OR * Subjects suspected of or diagnosed with the following Stage III per provider discretion or IV/metastatic malignancies: * Kidney: Clear Cell Renal Cell Carcinoma (ccRCC) * Bladder: Urothelial Carcinoma (UC) * Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with ICI therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate LDT tests that per clinician, render the patient eligible for…